A Phase 1 interventional study of BMS-986165 and Placebo in Autoimmune Diseases, sponsored by Bristol-Myers Squibb. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-18.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.
Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 18th largest by enrollment of the 113 interventional ones that give a count, is one of 2 that started in 2019, is one of 57 in phase 1, and was the 19th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:
Antengene Biologics Limited · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, United States, Australia and 17 more countries
Ages 18+
Peking University Third Hospital · Sites in China
Ages 18+
Vivacta Biotechnology (Shanghai) Co., Ltd. · Sites in China
Ages 18–65
The Children's Hospital of Zhejiang University School of Medicine · Sites in China
Ages 3+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 20 · Phase 3 10 · Phase 4 5
First in 2008; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 135 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 30 across the 113 interventional studies, 850 across the 12 observational. Of the 20 that completed or were terminated, 3 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
46 of 125 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 8 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
23 of the studies in Autoimmune Diseases with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT07470151Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyClinical Study of EVM18001 in the Treatment of Refractory Autoimmune Diseases | 2026-11 |
| NCT06318533YANRU WANGA Clinical Study of CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases | 2026-12-13 |
| NCT06340490Guangdong Ruishun Biotech Co., LtdA Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE) | 2026-12-31 |
| NCT06243159Shanxi Bethune HospitalJY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases | 2026-12-31 |
Add all 23 to your calendar (.ics) → With an account.
Among the 125 studies in Autoimmune Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Dose 1 on Day 1, and from Day 5 - 19.
Drug: BMS-986165
Participants will receive Dose 2 on Day 1, and from Day 5 - 19.
Drug: BMS-986165
Participants will receive placebo matching Dose 1 on Day 1, and from Day 5 - 19.
Other: Placebo
Participants will receive placebo matching Dose 2 on Day 1, and from Day 5 - 19.
Other: Placebo
Dose 1 or Dose 2 on Day 1, and from Days 5-19'
Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
Maximum Observed Plasma Concentration (Cmax) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of BMS-986165
Time frame: Day 1 to Day 4
Apparent Plasma Elimination Half-Life (T-HALF) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Apparent Oral Total Body Clearance (CLT/F) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Metabolic Ratio for AUC(INF) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[INF])
Time frame: Day 1 to Day 4
Metabolic Ratio for Cmax of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(Cmax)
Time frame: Days 1 to 4, Day 5, and Day 19
Apparent Volume of Distribution (Vz/F) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Time to Maximum Observed Plasma Concentration (Tmax) of BMS-986165
Time frame: Day 5 to Day 19
Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of BMS-986165
Time frame: Day 5 and Day 19
Effective Elimination Half-Life (T-HALFeff) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Trough Observed Plasma Concentration (Ctrough) of BMS-986165
Time frame: Day 2 to 20
Average Plasma Concentration at Steady State (Css-avg) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Accumulation Index (AI) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Metabolic Ratio for AUC(TAU) of Metabolite (BMT-153261 and BMT-158170) Over Parent (BMS-986165) - MR(AUC[TAU])
Time frame: Day 5 to Day 19
Degree of Fluctuation (DF) of BMS-986165
Time frame: Days 1 to 4, Day 5, and Day 19
Number of participants with Adverse Events (AEs)
Time frame: Up to Day 31
Number of Participants With Clinically Significant Change in Clinical Laboratory Values
Time frame: Up to Day 24
Number of Participants With Clinically Significant Change in Vital Signs
Time frame: Up to Day 24
Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)
Time frame: Up to Day 24
Number of Participants With Clinically Significant Change in Physical Examination
Time frame: Up to Day 24
Maximum Observed Plasma Concentration (Cmax) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Time to Maximum Observed Plasma Concentration (Tmax) of B Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Area Under The Plasma Concentration-Time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC(0-T)) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Area Under The Plasma Concentration-Time Curve From Time Zero Extrapolated To Infinite Time (AUC(INF)) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Apparent Plasma Elimination Half-Life (T-HALF) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Area Under the Plasma Concentration-Time Curve in a Dosing Interval (AUC(TAU)) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Effective Elimination Half-Life (T-HALFeff) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Trough Observed Plasma Concentration (Ctrough) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Average Plasma Concentration at Steady State (Css-avg) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Accumulation Index (AI) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Degree of Fluctuation (DF) of Metabolites BMT-153261 and BMT-158170
Time frame: Days 1 to 4, Day 5, and Day 19
Total Amount of Drug Recovered in Urine (URt) Following Single Oral Doses of BMS-986165
Time frame: Day 1 to Day 5
Total Percent of Administered Dose Recovered Unchanged in Urine (%URt) Following Single Oral Doses of BMS-986165
Time frame: Day 1 to Day 5
Renal Clearance (CLR) Following Single Oral Doses of BMS-986165
Time frame: Day 1 to Day 5
Ran from Apr 2019 to primary completion in Sep 2019, 5 months.
Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 5 months is below that.
Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib